基于PET的趋化因子受体2成像在实验性与疾病相关肺部炎症中的应用
研究在小鼠肺损伤模型和人类肺组织标本中表征了靶向趋化因子受体2(CCR2)的肽类PET示踪剂64Cu-DOTA-ECL1i。LPS损伤小鼠肺PET信号显著高于盐水对照组,阻断后及CCR2缺陷小鼠信号显著降低;COPD肺组织CCR2水平显著高于非病变组织,64Cu-DOTA-ECL1i放射自显影可检测。
要点
- 64Cu-DOTA-ECL1i可在小鼠肺损伤模型中PET检测CCR2相关炎症。
- COPD肺组织CCR2水平显著高于非病变肺组织,可用该示踪剂放射自显影检测。
- 该探针有望用于CCR2导向肺部炎症的PET无创检测,尚处临床转化前阶段。
核心结论
- 64Cu-DOTA-ECL1i是动物模型和人类组织中PET检测CCR2导向炎症的有前景工具,为临床转化迈出一步。
研究设计与样本
- 研究经机构动物与人类研究委员会批准,患者签署知情同意。
- 将7氨基酸CCR2结合肽(细胞外环1反向肽,ECL1i)偶联DOTA并标记64Cu或荧光染料。
- 野生型小鼠气管内给予LPS诱导肺损伤(n=19),CCR2缺陷小鼠(n=4)及盐水对照野生型小鼠(n=5)静脉注射64Cu-DOTA-ECL1i后行PET。
- 流式细胞术检测肺免疫细胞及体内结合荧光标记ECL1i的细胞。
- 非病变供体肺组织(n=11)与COPD肺移植受者肺组织(n=16)行CCR2免疫染色,其中COPD(n=6)行64Cu-DOTA-ECL1i放射自显影。
关键影像表现/征象
- LPS损伤后小鼠肺PET信号显著高于盐水对照组(平均4.43%ID/g vs 0.99%ID/g,P<.001)。
- 过量非放射性ECL1i阻断后PET信号显著降低(平均0.63%ID/g,P<.001)。
- CCR2缺陷小鼠PET信号显著降低(平均0.39%ID/g,P<.001)。
- ECL1i信号与小鼠肺单核细胞水平升高相关。
诊断标准与关键数值
- COPD肺组织CCR2水平显著高于非病变组织(中位数12.8% vs 1.2%细胞/样本,P=.002),经64Cu-DOTA-ECL1i放射自显影检测。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To characterize a chemokine receptor type 2 (CCR2)-binding peptide adapted for use as a positron emission tomography (PET) radiotracer for noninvasive detection of lung inflammation in a mouse model of lung injury and in human tissues from subjects with lung disease. Materials and Methods The study was approved by institutional animal and human studies committees. Informed consent was obtained from patients. A 7-amino acid CCR2 binding peptide (extracellular loop 1 inverso [ECL1i]) was conjugated to tetraazacyclododecane tetraacetic acid (DOTA) and labeled with copper 64 (64Cu) or fluorescent dye. Lung inflammation was induced with intratracheal administration of lipopolysaccharide (LPS) in wild-type (n = 19) and CCR2-deficient (n = 4) mice, and these mice were compared with wild-type mice given control saline (n = 5) by using PET performed after intravenous injection of 64Cu-DOTA-ECL1i. Lung immune cells and those binding fluorescently labeled ECL1i in vivo were detected with flow cytometry. Lung inflammation in tissue from subjects with nondiseased lungs donated for lung transplantation (n = 11) and those with chronic obstructive pulmonary disease (COPD) who were undergoing lung transplantation (n = 16) was evaluated for CCR2 with immunostaining and autoradiography (n = 6, COPD) with 64Cu-DOTA-ECL1i. Groups were compared with analysis of variance, the Mann-Whitney U test, or the t test. Results Signal on PET images obtained in mouse lungs after injury with LPS was significantly greater than that in the saline control group (mean = 4.43% of injected dose [ID] per gram of tissue vs 0.99% of injected dose per gram of tissue; P < .001). PET signal was significantly diminished with blocking studies using nonradiolabeled ECL1i in excess (mean = 0.63% ID per gram of tissue; P < .001) and in CCR2-deficient mice (mean = 0.39% ID per gram of tissue; P < .001). The ECL1i signal was associated with an elevated level of mouse lung monocytes. COPD lung tissue displayed significantly elevated CCR2 levels compared with nondiseased tissue (median = 12.8% vs 1.2% cells per sample; P = .002), which was detected with 64Cu-DOTA-ECL1i by using autoradiography. Conclusion 64Cu-DOTA-ECL1i is a promising tool for PET-based detection of CCR2-directed inflammation in an animal model and in human tissues as a step toward clinical translation. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Liu Y, Gunsten SP, Sultan DH, et al. PET-based Imaging of Chemokine Receptor 2 in Experimental and Disease-related Lung Inflammation. Radiology. 2017. PMID: 28045644. doi:10.1148/radiol.2016161409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。